cbdMD, Inc. (NYSEAMERICAN:YCBD)’s share price rose 7.4% during trading on Tuesday . The company traded as high as $0.79 and last traded at $0.78, approximately 366,656 shares traded hands during mid-day trading. A decline of 62% from the average daily volume of 961,086 shares. The stock had previously closed at $0.73.
YCBD has been the topic of a number of research reports. Benchmark cut their price objective on cbdMD from $9.00 to $7.00 and set a “speculative buy” rating on the stock in a report on Thursday, December 19th. Cantor Fitzgerald raised their price objective on cbdMD from $1.20 to $3.40 and gave the stock a “neutral” rating in a report on Monday, March 9th.
cbdMD (NYSEAMERICAN:YCBD) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.60. The firm had revenue of $10.41 million during the quarter.
In related news, CEO Raymond Scott Coffman bought 125,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 14th. The shares were acquired at an average cost of $1.09 per share, for a total transaction of $136,250.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last quarter, insiders have purchased 175,000 shares of company stock worth $182,250.
Large investors have recently made changes to their positions in the stock. Oxford Asset Management LLP acquired a new stake in cbdMD during the 4th quarter valued at approximately $50,000. Penserra Capital Management LLC acquired a new stake in cbdMD during the 3rd quarter valued at approximately $90,000. Lionsbridge Wealth Management LLC acquired a new stake in cbdMD during the 4th quarter valued at approximately $341,000. State Street Corp grew its stake in cbdMD by 17.4% during the 3rd quarter. State Street Corp now owns 150,518 shares of the company’s stock valued at $596,000 after purchasing an additional 22,318 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in cbdMD by 9.1% during the 4th quarter. Geode Capital Management LLC now owns 158,887 shares of the company’s stock valued at $359,000 after purchasing an additional 13,207 shares in the last quarter.
cbdMD Company Profile (NYSEAMERICAN:YCBD)
cbdMD, Inc produces and distributes various cannibidiol (CBD) products in the United States. It operates through three segments: Products, Licensing, and Entertainment. The Products segment produces and markets CBD tinctures, capsules, gummies, bath bombs, vape oils, topical creams, and animal treats and oils under the cdbMD brand.
Recommended Story: Most Volatile Stocks – What Investors Need to Know to Maximize ROI
Receive News & Ratings for cbdMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for cbdMD and related companies with MarketBeat.com's FREE daily email newsletter.